{"id":81861,"date":"2019-06-18T18:54:11","date_gmt":"2019-06-18T18:54:11","guid":{"rendered":"https:\/\/stockchase.com\/discover\/?p=81861"},"modified":"2019-06-18T18:54:11","modified_gmt":"2019-06-18T18:54:11","slug":"dns-manipulation-gene-editing-stocks","status":"publish","type":"post","link":"https:\/\/stockchase.com\/discover\/dns-manipulation-gene-editing-stocks\/","title":{"rendered":"Top Stocks with Groundbreaking Potential in the DNS Manipulation and Gene-Editing Markets"},"content":{"rendered":"

Bill Gates has known investments<\/a> in the gene-editing industry. <\/p>\n

Genetic Engineering is the field of science that manipulates DNA in order to change the gene expression. This technology is revolutionary as gene-editing and gene therapy could help people suffering from genetic disorders, as well as making humans more healthy. Applications include alleviating autoimmune disease, treatment of neurodegenerative disease, and other genetic disorders. <\/p>\n

The field is expanding quickly, with more and more companies investing heavily into genetic engineering, especially the CRISPR\/Cas9 System. CRISPR technology is considered the foremost precision gene editing tool. <\/p>\n

Here are the top companies in the field:<\/p>\n

👨‍⚕️ Healthcare<\/strong><\/p>\n

Agilent Technologies (A-N)<\/a>
\nThis company is a spin-off from Hewlett-Packard, which broke away in 1999. At the time, their IPO was the largest in history in Silicon Valley. They announced on June 18, 2019 the opening of a production facility in Colorado to produce nucleic acid-based therapeutics.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Agilent\t\t\t\t<\/a>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tAgilent Technologies (A-N) \u2014 Stockchase\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about A-N: Shares popped over 2% after reporting a solid quarter last Wednesday .<\/p>\n\t\t<\/a>\n\t<\/div>\n\t

\n\t\t\"stockchase.com\"\t\tstockchase.com\t<\/div>\n<\/div> <\/p>\n

Biogen IDEC Inc. (BIIB-Q)<\/a>
\nA biotechnology company that focuses on treatments for neurodegenerative, and autoimmune diseases. They recently experienced a sell-off following news that they shut down a previously promising drug for Alzheimer’s. They acquired Nightstar Therapeutics this year, who focus on adeno-associated virus based gene-therapies.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Biogen\t\t\t\t<\/a>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tBiogen IDEC Inc. (BIIB-Q) \u2014 Stockchase\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about BIIB-Q: Not impressed with products. Competitors out performing.\u00a0<\/p>\n\t\t<\/a>\n\t<\/div>\n\t

\n\t\t\"stockchase.com\"\t\tstockchase.com\t<\/div>\n<\/div> <\/p>\n

Charles River Labs Intl (CRL-N)<\/a>
\nA preclinical and clinical laboratory company for pharmaceutical and biotech firms. They are also a contractor that offers research and development outsourcing services. They offer a genetically engineered animal models and services, as well as CRISPR\/Cas9 System research.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Charles\t\t\t\t<\/a>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tCharles River Labs Intl (CRL-N) \u2014 Stockchase\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about CRL-N: Trevor Rose\u2019s Insights - Trevor\u2019s most-liked answers from 5i Research CRL provides drug discovery and safety testing services and is now trading at 22.6 times' Forward P\/E (historical averages range from 19x to 33x). In the last five years, revenue growth was quite healthy, averaging around 12% on average, largely driven through…<\/p>\n\t\t<\/a>\n\t<\/div>\n\t

\n\t\t\"stockchase.com\"\t\tstockchase.com\t<\/div>\n<\/div> <\/p>\n

Novartis AG (NVS-N)<\/a>
\nOne of the largest pharmaceutical companies based out of Switzerland. They are working on a drug called Kymriah that has the ability to reprogram a patient\u2019s own immune cells.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Novartis\t\t\t\t<\/a>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tNovartis AG (NVS-N) \u2014 Stockchase\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about NVS-N: If the economy slows down, you need a good pharma stock. Novartis was stuck in a rut until the current CEO started in 2018. He made a number of key acquisitions without paying and including smaller companies (they had overpaid in the past), focusing on their most lucrative divisions: drugs to treat…<\/p>\n\t\t<\/a>\n\t<\/div>\n\t

\n\t\t\"stockchase.com\"\t\tstockchase.com\t<\/div>\n<\/div> <\/p>\n

Regeneron Pharmaceuticals Inc (REGN-Q)<\/a>
\nA biotechnology company that has multiple key drugs, including Eylea for macular degeneration. They have one of the largest human DNA sequencing project that will help with drug discovery and development.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Regeneron\t\t\t\t<\/a>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tRegeneron Pharmaceuticals Inc (REGN-Q) \u2014 Stockchase\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about REGN-Q: It's lost a third of its market cap and the selling is overdone. Now, is a buying opportunity.<\/p>\n\t\t<\/a>\n\t<\/div>\n\t

\n\t\t\"stockchase.com\"\t\tstockchase.com\t<\/div>\n<\/div> <\/p>\n

Sanofi-Aventis (SNY-N)<\/a>
\nA french pharmaceutical company out of Paris that is the fifth largest in sales. They recently announced an over one billion dollar research deal with Denali Therapeutics for treatments for neurological and systemic inflammatory diseases.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Sanofi-Aventis\t\t\t\t<\/a>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tSanofi-Aventis (SNY-N) \u2014 Stockchase\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about SNY-N: (A Top Pick Jun 05\/25, Down 6.5%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with SNY has triggered its stop at $47.\u00a0 To remain disciplined, we recommend covering the position at this time.\u00a0\u00a0<\/p>\n\t\t<\/a>\n\t<\/div>\n\t

\n\t\t\"stockchase.com\"\t\tstockchase.com\t<\/div>\n<\/div> <\/p>\n

Thermo Fisher Scientific (TMO-N)<\/a>
\nA biotechnology and pharmaceutical lab equipment company. They are paying down debt and have made some acquisitions that will grow well over the next couple of years.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Thermo\t\t\t\t<\/a>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tThermo Fisher Scientific (TMO-N) \u2014 Stockchase\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about TMO-N: (A Top Pick Nov 05\/25, Down 18%) Demand from biopharma and research labs is improving. Core business has a healthy outlook. Have a big backlog and smoother execution are a growth engine. Is trading below historic valuations. Has 19% upside.<\/p>\n\t\t<\/a>\n\t<\/div>\n\t

\n\t\t\"stockchase.com\"\t\tstockchase.com\t<\/div>\n<\/div> <\/p>\n

United Therapeutics Corp. (UTHR-Q)<\/a>
\nAn American biotechnology company. Their primary drug therapy is for pulmonary disease. They acquired SteadyMed Therapeutics, a competitor with whom they were locked in a legal dispute with, last year.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"United\t\t\t\t<\/a>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tUnited Therapeutics Corp. (UTHR-Q) \u2014 Stockchase\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about UTHR-Q: (A Top Pick Apr 18\/24, Up 46.8%)Stockchase Research Editor: Michael O\u2019Reilly Our PAST TOP PICK with UTHR has triggered its stop at $349. \u00a0To remain disciplined, we recommend covering the position at this time. \u00a0This will result in a net investment gain of 51%, when combined with our previous guidance. \u00a0<\/p>\n\t\t<\/a>\n\t<\/div>\n\t

\n\t\t\"stockchase.com\"\t\tstockchase.com\t<\/div>\n<\/div> <\/p>\n

Illumina Inc. (ILMN-Q)<\/a>
\nOne of the only companies that can do high volume DNA sequencing. They have brought down the cost of genetic sequencing to retail levels. They are becoming more available outside of research for commercial use in clinics.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Illumina\t\t\t\t<\/a>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tIllumina Inc. (ILMN-Q) \u2014 Stockchase\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about ILMN-Q: Likes it long term. China is 7% of their sales and has been declining the past 3 years. Has $1 billion in free cash flow a year. A high gross-margin business but it will be noisy for a while.<\/p>\n\t\t<\/a>\n\t<\/div>\n\t

\n\t\t\"stockchase.com\"\t\tstockchase.com\t<\/div>\n<\/div> <\/p>\n

Gilead Sciences Inc. (GILD-Q)<\/a>
\nAn American biopharmaceutical company that is doing research on treating cancer using DNA targets to control it. They also released great results for a HIV treatment.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Gilead\t\t\t\t<\/a>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tGilead Sciences Inc. (GILD-Q) \u2014 Stockchase\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about GILD-Q: He had owned it for 10 years at a time when it had a blockbuster drug that cured hepatitis. Gilead took profits and invested them into HIV drugs. As with other drug companies holding patents on blockbuster drugs with expiry dates, don't buy this one.<\/p>\n\t\t<\/a>\n\t<\/div>\n\t

\n\t\t\"stockchase.com\"\t\tstockchase.com\t<\/div>\n<\/div> <\/p>\n

Bristol Myers Squibb (BMY-N)<\/a>
\nThey got hit due to problems with the Celegene acquisition. Some shareholders like it, others don\u2019t. They have an innovative pipeline and their drugs using genetic technology has performed well, as well as the biotech that will come under their wing from Celegene.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Bristol\t\t\t\t<\/a>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tBristol Myers Squibb (BMY-N) \u2014 Stockchase\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about BMY-N: Has never been this cheap. Has high hopes for their new central nervous system drug; it if doesn't work, he will sell BMY.<\/p>\n\t\t<\/a>\n\t<\/div>\n\t

\n\t\t\"stockchase.com\"\t\tstockchase.com\t<\/div>\n<\/div> <\/p>\n

Roche Holding (RHHBY-OTC)<\/a>
\nA Swiss multinational healthcare company. They acquired a biotech firm that does research and development for all their future products. They have some promising drugs for multiple sclerosis and cancer treatment.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Roche\t\t\t\t<\/a>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tRoche Holding (RHHBY-OTC) \u2014 Stockchase\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about RHHBY-OTC: A month ago, they bought Carmot Therapeutics, a private clinical-stage biotech, though its drugs are only in phase 2 trials. Why did they buy this? So they can work on their own weight-loss drug, which are hot now.<\/p>\n\t\t<\/a>\n\t<\/div>\n\t

\n\t\t\"stockchase.com\"\t\tstockchase.com\t<\/div>\n<\/div> <\/p>\n

CRISPR Therapeutics AG (CRSP-Q)<\/a>
\nOne of the smaller companies developing transformative gene medications. Their gene-editing tool is used to splice DNA that has the potential of curing diseases such as Huntington’s Chorea and cancer.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"CRISPR\t\t\t\t<\/a>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tCRISPR Therapeutics AG (CRSP-Q) \u2014 Stockchase\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about CRSP-Q: He sees this company mentioned in many science papers, but the stock has been a tough own. Overall, he likes it. Buy some now and more if it goes lower. How can this company keep losing money?<\/p>\n\t\t<\/a>\n\t<\/div>\n\t

\n\t\t\"stockchase.com\"\t\tstockchase.com\t<\/div>\n<\/div> <\/p>\n","protected":false},"excerpt":{"rendered":"

Bill Gates has known investments in the gene-editing industry. Genetic Engineering is the field of science that manipulates DNA in order to change the gene expression. This technology is revolutionary as gene-editing and gene therapy could help people suffering from […]<\/p>\n","protected":false},"author":9,"featured_media":82132,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"cwp_meta_box_check":"No","cwp_rev_product_name":"","cwp_rev_product_image":"","wppr_links":[],"cwp_rev_price":"","wppr_options":[],"wppr_pros":[],"wppr_cons":[],"footnotes":""},"categories":[17],"tags":[],"class_list":["post-81861","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-lists"],"wppr_data":{"cwp_meta_box_check":"No"},"_links":{"self":[{"href":"https:\/\/stockchase.com\/discover\/wp-json\/wp\/v2\/posts\/81861","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stockchase.com\/discover\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stockchase.com\/discover\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stockchase.com\/discover\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/stockchase.com\/discover\/wp-json\/wp\/v2\/comments?post=81861"}],"version-history":[{"count":0,"href":"https:\/\/stockchase.com\/discover\/wp-json\/wp\/v2\/posts\/81861\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stockchase.com\/discover\/wp-json\/wp\/v2\/media\/82132"}],"wp:attachment":[{"href":"https:\/\/stockchase.com\/discover\/wp-json\/wp\/v2\/media?parent=81861"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stockchase.com\/discover\/wp-json\/wp\/v2\/categories?post=81861"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stockchase.com\/discover\/wp-json\/wp\/v2\/tags?post=81861"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}